RTRalph Torgler

Ralph Torgler

*This is an algorithmically generated author record based on publicly available information.

Ralph Torgler has a total of 9 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks

    by Chloe Orkin, Ralph Torgler, Rebecca Dawson, Ian W. Holloway, Christian Hoffmann

    Human mpox, caused by the mpox virus, is a reemerging viral zoonosis that has gained global attention due to recent Clade IIb outbreaks outside of Africa, as well as ongoing Clade Ia and Ib outbreaks in the Democratic Republic of Congo (DRC) and surrounding regions. Since the start of these outbreaks in 2022, approximately 160,000 people have been affected across more than 100 countries. People with human immunodeficiency virus (HIV; hereafter referred to as PWH) have been disproportionately affected, accounting for approximately 50% of all cases. Mpox is typically a self-limiting illness causing smallpox-like symptoms lasting 2–4 weeks, which can cause significant pain and morbidity. People with uncontrolled or advanced HIV face an elevated risk of severe mpox, secondary complications, and worse outcomes. Vaccination with second- and third-generation vaccinia-based smallpox vaccines has emerged as an important tool in mpox prevention, alongside behavioural modification to mitigate risk. However, only the third-generation, live-attenuated, non-replicating vaccine, modified vaccinia Ankara (MVA-BN [Bavarian Nordic]), is approved for use in PWH. Real-world estimates suggest that two doses of MVA-BN administered as pre-exposure prophylaxis confers vaccine effectiveness in the range of 66–90%. Additionally, MVA-BN has been widely demonstrated to have an acceptable safety profile. This narrative review explores the changing epidemiology, clinical manifestations, and outcomes of mpox in PWH. We also summarise evidence from the Clade IIb outbreaks on the effectiveness and safety of MVA-BN among PWH. Despite progress in our understanding, knowledge gaps persist regarding vaccine performance in individuals with advanced immunosuppression. Furthermore, due to the emergent nature of outbreaks in the DRC and surrounding areas, limited information is available regarding implications for PWH in the context of Clade Ia and Ib. We aim to provide healthcare providers, community stakeholders, and researchers with a foundational understanding of mpox in PWH and the role of MVA-BN in mpox prevention among this group, while highlighting areas of uncertainty. These insights may be helpful in the planning of future research and to inform strategies for the prevention and management of mpox among PWH, particularly those with advanced or uncontrolled HIV.


  • Open Access

    Fast-Track to Protection? A Review of Encepur’s Express Dosing Schedule for Tick-Borne Encephalitis

    by Kyra Zens, Ralph Torgler, Michael Horn, Carsten Schade Larsen

    Cases of confirmed tick-borne encephalitis (TBE) have increased dramatically over the last 30 years, highlighting growing endemicity across Eurasia. Two preventative vaccines, Encepur® (Bavarian Nordic A/S, Hellerup, Denmark) and FSME-Immun® (Pfizer Ireland Pharmaceuticals, Cork, Ireland), are licensed in Europe. For both vaccines, primary immunisation consists of a three-dose regimen, administered over approximately one year using “Conventional” dosing schedules. Both vaccines can also be administered using “Rapid” schedules, which shorten the interval between the first two doses but still take around a year to complete. Currently, only Encepur offers an approved “Express” schedule, whereby all three priming doses are given within 21 days. The effectiveness of TBE vaccination is markedly higher in individuals who receive ≥3 doses, compared with those who receive only one or two doses, indicating the importance of series completion. Moreover, seropositivity takes several weeks to develop after vaccination. As such, individuals are advised to initiate vaccination before peak tick season to allow sufficient time to develop protective immunity during periods of highest risk. Despite these considerations, vaccine uptake and series completion remain suboptimal in TBE-endemic regions. Furthermore, many vaccinees—including travellers with limited time before departure and residents of endemic areas—do not initiate vaccination until peak tick season, when risk is greatest. Broader use of Encepur’s Express schedule may help to address these challenges. The Express schedule’s 21-day timeframe may help to increase series completion by reducing drop-offs associated with prolonged dosing intervals. Additionally, it can support timely protection by enabling series completion, with sufficient time post-vaccination to develop protective immunity, all within a single-risk season, even among late initiators. In this narrative review, we evaluate the safety and immunogenicity of Encepur’s Express schedule and discuss its potential utility across a broader range of vaccinees. These insights may help inform TBE vaccine recommendations and support efforts towards improving vaccination strategies amid increasing TBE risk.

  • Open Access

    What makes patients tick? Vaccine preferences against tick-borne encephalitis in four European countries

    by Charlotta Zacharias, Ralph Torgler, Jennifer Cummins

    Background: We explored vaccine motivation and preferences for tick-borne encephalitis (TBE) vaccine attributes among participants in TBE-endemic countries in Europe. Methods: An online survey was conducted among the general public in Austria, Germany, Switzerland, and Sweden. Participants were ≥ 18 years old, open to receiving vaccines, and living in, or regularly traveling to, TBE-endemic regions in the aforementioned countries. Participants were asked about their general vaccine knowledge and motivations for vaccination, before rating the importance of TBE vaccine attributes, such as efficacy, safety, dosing schedule, and booster interval. Thereafter, participants were shown three hypothetical TBE vaccine profiles with different combinations of attributes. Assuming equal efficacy and safety, participants were asked to select their preferred profile from 12 screens as part of a discrete-choice conjoint analysis. Utility scores were calculated to show the importance of each attribute. Data are presented for the overall survey group and by age and gender, using t-tests to compare means. Results: For 73% of participants (n = 1003/1379), self-protection was among the top three reasons to get vaccinated. Disease severity, protection of children or family, and advice or recommendation from a doctor/healthcare professional (HCP) were top three reasons for over half of participants. The majority (58–69%) agreed or strongly agreed that they trust their doctor/HCP on the subject of vaccines, they rely on their doctor/HCP’s vaccine knowledge, and they prefer their doctor/HCP to make recommendations on which vaccines they or their families should take. Efficacy and safety were the most important standalone TBE vaccine attributes; however, among TBE vaccine profiles including 3-, 5- and 10-year booster intervals, the 10-year booster interval was the most influential attribute level when choosing a preferred vaccine profile (utility score: 0.58 [standard error: 0.01]). Differences in motivators and preferences were observed between age and gender subgroups. Conclusion: The high level of doctor/HCP reliance highlights the key role doctors/HCPs play in influencing vaccine decision-making. Booster interval was the biggest driver of choice when selecting a hypothetical TBE vaccine profile, with the strongest preference for a 10-year booster interval. These findings could be used to inform TBE vaccination recommendations and in the further development of TBE vaccines.